

1
2
3 **1 Affinity transfer to the archaeal extremophilic Sac7d protein by**
4
5
6 **2 insertion of a CDR**
7

8
9
10
11 4 Sabino Pacheco^{1,2,3,4}, Ghislaine Béhar^{1,2,3}, Mike Maillason^{1,2,3,5}, Barbara
12
13 5 Mouratou^{1,2,3}, Frédéric Pecorari^{1,2,3*}
14

15
16
17 7 ¹CRCNA - UMR 892 INSERM, ²6299 CNRS, ³University of Nantes, 8 quai
18
19 8 Moncoussu, BP 70721, 44007 Nantes, Cedex 1, France.

20
21 9 ⁴Institut Pasteur, CNRS UMR 3528, Unité de Microbiologie Structurale, 25 rue du Dr.
22
23 10 Roux, 72724 Paris Cedex 15, France.
24

25
26 11 ⁵Plate-forme IMPACT biogenouest, 8 quai Moncoussu, BP 70721, 44007 Nantes,
27
28 12 Cedex 1, France.
29

30
31
32 14 * Address for correspondence: Université de Nantes, CRCNA - UMR 892 INSERM,
33
34 15 6299 CNRS, 8 quai Moncoussu, BP 70721, 44007 Nantes Cedex 1, France. Tel: 33-2
35
36 16 40 41 28 51; E-mail: frederic.pecorari@univ-nantes.fr
37
38
39

40
41
42
43 18 **Running title:** Affinity transfer to the extremophilic Sac7d protein
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

20 **ABSTRACT**

21 Artificially transforming a scaffold protein into binders often consists of
22 introducing diversity into its natural binding region by directed mutagenesis. We have
23 previously developed the archaeal extremophilic Sac7d protein as a scaffold to derive
24 affinity reagents (Affitins) by randomization of either a flat surface or a flat surface
25 and two short loops with natural lengths. Short loops are believed to contribute to
26 stability of extremophilic proteins, and loop extension has been reported detrimental
27 for the thermal and chemical stabilities of mesophilic proteins. In this work, we
28 wanted to evaluate the possibility of designing target-binding proteins based on Sac7d
29 by using a complementary determining region (CDR). To this aim, we inserted into
30 three different loops a 10 residues CDR from the cAb-Lys3 anti-lysozyme camel
31 antibody. The chimeras obtained were as stable as wild type Sac7d at extreme pH and
32 their structural integrity was supported. Chimeras were thermally stable, but with T_m s
33 from 60.9°C to 66.3°C (*cf.* 91°C for Sac7d) which shows that loop extension is
34 detrimental for thermal stability of Sac7d. The loop 3 enabled anti-lysozyme activity.
35 These results pave the way for the use of CDR(s) from antibodies and/or extended
36 randomized loop(s) to increase the potential of binding of Affitins.

37

38 **KEYWORDS**

39 Sac7d, affinity transfer, CDR insertion, Affitin, extremophilic

40

41 INTRODUCTION

42 The continuous development of protein based affinity reagents with favorable
43 properties is essential for research, clinical and industrial applications. While
44 antibodies are the most widely used proteins to develop binders, another class of
45 proteins termed “alternative scaffold proteins” has emerged during the last two
46 decades (for reviews see (Binz *et al.*, 2005, Gebauer and Skerra, 2009)). These
47 proteins are usually small (less than 15 kDa), easy to engineer, stable and expressed
48 with high yields in *Escherichia coli*.

49 The transformation of proteins into binders requires the introduction of diversity
50 into a region that will become the binding site by creating libraries from which
51 variants are isolated via a selection/screening step. This process is well described for
52 various scaffolds such as Affibodies, DARPins, Anticalins, Monobodies and Affitins.
53 The choice of the region in which to introduce diversity in a protein is usually driven
54 by how the protein binds its natural ligand: it can be a surface (Binz *et al.*, 2004,
55 Mouratou *et al.*, 2007, Nord *et al.*, 1997), or loops (Beste *et al.*, 1999, Koide *et al.*,
56 1998). Thus, scaffold proteins are often obtained by replacement mutagenesis to
57 maintain the natural mode of binding.

58 However, it is important to know if the natural mode of binding is the most
59 efficient to derive affinity proteins against a wide range of targets. For example,
60 inserting flexible loops, which often guide protein binding events as observed for
61 CDRs of antibodies, onto a scaffold that originally used only a surface for binding can
62 extend its potential to reach buried epitopes in protein grooves or catalytic sites
63 (Correa *et al.*, 2014, Koide *et al.*, 2012, Schilling *et al.*, 2014).

64 It has been reported that increasing the length of loops in Rop and chymotrypsin
65 inhibitor-2 proteins can result in a decrease in the overall stability of the proteins

1
2
3 66 (Ladurner and Fersht, 1997, Nagi and Regan, 1997) while for the protein inhibitor of
4
5 67 neuronal nitric oxide synthase (PIN-bodies), no significant destabilization could be
6
7 68 observed (Bes *et al.*, 2006). For the fibronectin type III domain, also known as the
8
9 69 Monobody scaffold, destabilization effects could be observed or not depending on
10
11 70 which loop was extended (Batori *et al.*, 2002).
12
13

14 71 Overall, these studies suggest that the detrimental consequences of extending loops
15
16 72 seem at least protein- and loop-dependent, and therefore difficult to predict. This
17
18 73 makes even more challenging the design of an unnatural mode of binding, compared
19
20 74 to a conservative one, in a protein without altering the favorable properties for which
21
22 75 it was chosen as a scaffold.
23
24

25 76 We have developed artificial affinity proteins (Affitins) derived from
26
27 77 extremophilic proteins from the “7kDa DNA-binding” family found in Archaea
28
29 78 (*Sulfolobus*, *Acidianus*, and *Metallospharea* genus for examples), such as Sac7d
30
31 79 (Behar *et al.*, 2013, Buddelmeijer *et al.*, 2009, Krehenbrink *et al.*, 2008, Mouratou, *et*
32
33 80 *al.*, 2007). This was primarily done by recruiting residues of the β -sheet surface
34
35 81 originally involved in the binding of DNA. As an important step in exploring how
36
37 82 diversity can be efficiently introduced into this scaffold, we reported that Affitins are
38
39 83 able to bind different epitopes of the same target via two different modes of binding:
40
41 84 involving a flat surface or involving a flat surface and two short loops with natural
42
43 85 lengths (Behar, *et al.*, 2013).
44
45
46

47 86 Sac7d is a hyperthermostable protein with a T_m of 90°C (Edmondson and Shriver,
48
49 87 2001, McCrary *et al.*, 1996, Mouratou, *et al.*, 2007) and is chemically resistant from
50
51 88 pH = 0 up to pH = 12 (Behar, *et al.*, 2013). Consequently, these unusual stabilities can
52
53 89 be expected to be helpful in reshaping loops. However, it is assumed that short loops
54
55 90 contribute to the stability of extremophilic proteins (Kumar and Nussinov, 2001,
56
57
58
59
60

1
2
3 91 Thompson and Eisenberg, 1999). Thus, extending loops in Sac7d could be
4
5 92 destabilizing.

6
7 93 We reported that the loop 2 of Affitin D1 is involved in the recognition of human
8
9 94 IgG (Behar, *et al.*, 2013), and we recently designed a novel generation of binders with
10
11 95 enzymatic inhibition properties by artificially extending this loop with four
12
13 96 randomized residues. This was achieved while conserving the favorable properties of
14
15 97 Affitins (Correa, *et al.*, 2014). In this work we wanted to address three main
16
17 98 questions. Can insertion of a CDR into different loops result in a folded Sac7d? Are
18
19 99 the chimeric proteins obtained still hyperthermostable? Is the potential of each loop to
20
21 100 introduce recognition of a target equivalent? With these aims, we inserted an anti-
22
23 101 lysozyme CDR of ten residues from a camel antibody (Desmyter *et al.*, 1996) at three
24
25 102 positions where there is a loop in Sac7d and studied the function and stability
26
27 103 properties of the resulting chimeric proteins.
28
29
30
31

32 104

33 105 **MATERIALS & METHODS**

34 106 **Molecular biology**

35
36
37 107 The sequence ¹⁰⁰STIYASYYES¹⁰⁹ was inserted between the residues ⁹KG¹⁰,
38
39 108 ²⁷GK²⁸ and ³⁷NG³⁸ of the Sac7d protein. This sequence corresponds to the CDR3
40
41 109 sequence involved in hen egg white lysozyme (HEWL)-binding of cAb-Lys3
42
43 110 antibody but with a C109S substitution in order to avoid an intermolecular disulfide
44
45 111 bond between the thiol groups. Mutants were named mL1, mL2 and mL3,
46
47 112 respectively. Mutagenesis was carried out by two-step PCR using the *sac7d* wild-type
48
49 113 gene as template (5'-
50
51 114 GGATCCGTGAAAGTGAAATTTAAATATAAAGGCGAAGAAAAAGAAGTGG
52
53 115 ACACCAGCAAGATCAAGAAAGTTTGGCGTGTGGGCAAATGGTGAGCTTT
54
55
56
57
58
59
60

1
2
3 116 ACCTACGACGACAACGGCAAGACCGGCCGTGGCGCCGTGAGCGAGAAAG
4
5 117 ATGCCCCGAAAGAGTTATTAGATATGTTAGCGCGTGC GGAACGTGAAAAA
6
7 118 AAGCTT-3'). The first PCR was performed with forward primers 5'-
8
9 119 GAAAGTTTGGCGTGTGGGCTCTACCATTTATGCGTCTTATTATGAAAGC
10
11 120 AAAATGGTGAGCTTTACCTACG-3' and 5'-
12
13 121 GGTGAGCTTTACCTACGACGACA ACTCTACCATTTATGCGTCTTATTATG
14
15 122 AAAGCGGCAAGACCGGCCGTGGCGC-3' to introduce the CDR3 (bold
16
17 123 sequence) in mL2 and mL3, respectively. The reverse primer 5'-
18
19 124 ATATAAAGCTTTTTCTCGGTTCCGCAC-3' was common to both mutants and
20
21 125 contains the HindIII restriction site (underlined sequence). To obtain the complete
22
23 126 gene, a second PCR was performed using the first PCR fragments as reverse
24
25 127 "megaprimers" and forward primer 5'-ATATAGGATCCGTGAAAGTGAAATT-3',
26
27 128 which contains the BamHI restriction site. To obtain mL1 protein, only one-step PCR
28
29 129 was performed using the forward primer 5'-
30
31 130 TATGGATCCGTGAAAGTGAAATTTAAATATAAATCTACCATTTATGCGTC
32
33 131 TTATTATGAAAGCGGCGAAGAAAAAGAAGTGGAC-3' and the same reverse
34
35 132 primer with the HindIII restriction site. PCR products were cloned in pFP1001 vector,
36
37 133 which is a modified version from pQE30 that enables the fusion of RGS-6His tag at
38
39 134 the N-terminal.
40
41
42
43
44
45
46
47

136 **Production and purification of proteins**

137 Proteins were produced in *E. coli* DH5 α harboring the plasmid pFP1001 with
138 cloned genes. All cultures were grown to reach a DO₆₀₀ of about 0.6 in 2xYT and the
139 protein expression was induced with 0.5 mM IPTG over night at 30°C. Cells were
140 pelleted by centrifugation at 4,000 g for 15 minutes and resuspended in lysis buffer

1
2
3 141 (50 mM NaPO₄ pH 7.5, 500 mM NaCl, 20 mM imidazole) containing Bugbuster
4
5 142 solution (Novagene). Cells were lysed using an EmulsiFlex homogenizer and
6
7 143 centrifuged at 18,000 g for 45 min. Supernatant was used for purification by
8
9 144 immobilized metal ion affinity chromatography (IMAC). Then, the proteins were
10
11 145 injected into a Superdex75 16/60 column (GE Healthcare) equilibrated with 25 mM
12
13 146 Tris-HCl pH 8.0, 500 mM NaCl. Monomeric purified proteins were dialyzed
14
15 147 overnight at 4°C against PBS buffer pH 7.4 (130 mM NaCl, 2.7 mM KCl, 10 mM
16
17 148 Na₂HPO₄, 2 mM KH₂PO₄) and quantified spectrophotometrically at 280 nm using an
18
19 149 extinction coefficient of 8250 M⁻¹ cm⁻¹ for wild type Sac7d and 12090 M⁻¹ cm⁻¹ for
20
21 150 chimeric proteins.
22
23
24
25

151

152 **Analysis of secondary structure content of proteins**

153 Far-UV CD spectra were recorded from 190 to 260 nm on a JASCO J-810
154 instrument (Jasco) using a quartz cell with a path length of 0.2 cm (Hellma). The
155 temperature of the sample was maintained at 20°C with a programmable Peltier single
156 cell holder PTC-423S. Measurements were recorded in step mode (interval, 1 nm;
157 bandwidth, 2 nm; response time, 0.125 s) and averaged over three scans. Proteins
158 were diluted to a final concentration of 0.25 mg/ml in PBS. A baseline correction was
159 made with the buffer. Secondary structure prediction was performed with the
160 Dichroweb server (<http://dichroweb.cryst.bbk.ac.uk/html/home.shtml>) using the
161 CDSSTR algorithm (Whitmore and Wallace, 2004, Whitmore and Wallace, 2008).
162

162

163 **pH stability of proteins**

164 To study their pH stability, proteins were diluted to 0.33 mg/ml in buffered
165 solution or a strong acid corresponding to each pH unit from 0 to 14. Except for HCl,
166

1
2
3 166 the following solutions were adjusted to the required pH with HCl or NaOH: pH 0 = 1
4
5 167 M HCl, pH 1 = 0.1 M HCl, pH 2 = 50 mM NaH₂PO₄, pH 3 = 50 mM NaH₂PO₄, pH 4
6
7 168 = 50 mM acetic acid, pH 5 = 50 mM acetic acid, pH 6 = 50 mM MES, pH 7 = 50 mM
8
9 169 phosphoric acid, pH 8 = 50 mM NaH₂PO₄, pH 9 = 50 mM Tris base, pH 10 = 50 mM
10
11 170 methylamine, pH 11 = 50 mM methylamine, pH 12 = 50 mM NaH₂PO₄, pH 13 = 0.1
12
13 171 M NaOH, pH 14 = 1 M NaOH. All the buffers contained NaCl 300 mM. Protein
14
15 172 samples were incubated overnight in these buffers at room temperature and CD
16
17 173 spectra were recorded at 20°C as described above, using a quartz cell with a path
18
19 174 length of 0.2 cm (Hellma).
20
21
22
23
24

25 176 **Thermal stability of proteins**

26
27 177 Thermally-induced unfolding of proteins was studied by circular dichroism as
28
29 178 described by Edmondson and Shriver (Edmondson and Shriver, 2001). Briefly,
30
31 179 proteins were dialyzed against a 1 mM potassium acetate buffer (pH 5.5). Proteins
32
33 180 were then diluted to 0.02 mg/ml in this buffer. Ellipticity was recorded at 205 nm
34
35 181 (bandwidth, 5 nm; response time, 4 s) using a quartz cell with a path length of 1 cm
36
37 182 (Hellma) and curves were normalized. The melting temperatures were evaluated from
38
39 183 the collected data as midpoints of the thermal transitions using GraphPad Prism
40
41 184 software and a two-state transition model assuming that there is a change in heat
42
43 185 capacity of the folded and unfolded forms (Greenfield, 2006, Mouratou, *et al.*, 2007).
44
45
46
47
48

49 187 **Detection of DNA binding activity by fluorescence**

50
51 188 This assay was performed as previously reported (McAfee *et al.*, 1996) with some
52
53 189 modifications. Tryptophan emission fluorescence was recorded with a Tecan Infinite
54
55 190 M1000 spectrofluorimeter. Proteins (5 μM) were incubated in the absence or presence
56
57
58
59
60

1
2
3 191 of calf thymus DNA (Sigma) at a final concentration of 200 μM in PBS buffer pH 7.4.
4
5 192 An extinction coefficient of $6600 \text{ M}^{-1} \text{ cm}^{-1}$ was used to estimate the concentration of
6
7 193 calf thymus DNA at 260 nm. The emission spectra were recorded at 25°C from 300 to
8
9 194 400 nm with 2 nm-increments using an excitation wavelength of 285 nm and a flat 96-
10
11 well microplate (Greiner). PBS buffer spectra were subtracted from data obtained and
12
13
14 196 a normalization of the curves was performed with equation 1:

15
16 197
$$F_i = F - F_{min} / F_{max} - F_{min} \quad (\text{Eq.1})$$

17
18 198 where F_{min} and F_{max} are the fluorescence minima and maxima, F is the
19
20 199 fluorescence recorded for each data point and F_i the normalized fluorescence
21
22 200 intensity.

23
24
25 201 DNA-binding affinity was determined by incubation of the proteins ($5\mu\text{M}$) with
26
27 202 several concentrations of DNA (10 to 200 μM) and the quenching fluorescence was
28
29 203 recorded at 345 nm. Values were normalized with equation 1 and transformed with
30
31 204 equation 2:

32
33
34 205
$$F_Q = 1 - F_i \quad (\text{Eq.2})$$

35
36 206 Data were fitted to a nonlinear regression curve with GraphPad Prism software to
37
38 207 determine affinity parameters.

39
40
41 208

42
43 209 **Detection of DNA binding activity by electrophoretic mobility shift assay**
44
45 210 **(EMSA)**

46
47 211 For this assay a DNA probe of 200 bp was produced by PCR using wild type *sac7d*
48
49 212 gene as template. Approximately 200 ng of this probe was incubated with varying
50
51 213 quantities of purified wild type Sac7d or chimeric proteins (0, 0.6, 1.2, 2.5, 5, and 10
52
53 214 μM) in PBS buffer pH 7.0 in a total volume of 10 μl at room temperature for 30 min.
54
55
56 215 The samples were resolved by electrophoresis in 6% acrylamide gels with TBE buffer
57
58
59
60

1
2
3 216 at constant voltage. After electrophoresis, gels were stained with GelGreen nucleic
4
5 217 acid stain (Biotium).

6
7 218

9 219 **Detection of anti-HEWL activity by ELISA**

10
11 220 An ELISA plate was coated with 50 ng/well of HEWL (Sigma) or casein in PBS
12
13
14 221 buffer and blocked with 0.5% BSA. Then, wild type Sac7d or chimeric proteins were
15
16 222 added. After incubation, unbound proteins were removed by washing steps. Bound
17
18 223 proteins were detected with an anti-RGS-6His antibody conjugated with horseradish
19
20 224 peroxidase (Qiagen) diluted 1:5000. Finally, ortho-phenylenediamine (1 mg/ml OPD,
21
22 225 0.05% H₂O₂, 100 mM sodium citrate, pH 5.0) was used as the substrate for detection.
23
24 226 Absorbance was recorded at 450 nm with a Tecan Infinite M1000 plate reader. ELISA
25
26 227 was performed at 25°C with 1 h of incubation for each step.
27
28
29

30 228

31 229 **Affinity determination of anti-HEWL activity by surface plasmon resonance** 32 33 34 230 **(SPR)**

35
36 231 Affinity binding assays using SPR were performed with a BIAcore 2000
37
38 232 instrument (GE Healthcare). HEWL diluted to 3 µg/ml in a sodium acetate buffer (pH
39
40 233 5.5) was immobilized (300 RU) by amine coupling on a CM5 chip activated
41
42 234 previously with N-hydroxysuccinimide and 1-ethyl-3-(3-dimethylaminopropyl)
43
44 235 carbodiimide. Residual reactive groups on the surface were inactivated with 1 M
45
46 236 ethanolamine, pH 8.5. Kinetic measurements for affinity determinations of chimera
47
48 237 were performed with size-exclusion purified proteins injected at concentrations
49
50 238 ranging from 0.28 to 35.9 µM at a flow rate of 40 µl/min. Association and
51
52 239 dissociation times were controlled at 3 and 10 min, respectively. After each binding
53
54 240 cycle the chip was regenerated by injection of NaOH 5 mM for 30 s. Data were
55
56
57
58
59
60

1
2
3 241 evaluated using BIAeval software (BIAcore) with a heterogeneous binding model and
4
5 242 a global fitting procedure (Karlsson and Falt, 1997).
6

7 243
8

9 244 **RESULTS**

10
11 245 To evaluate the possibility of designing target-binding proteins based on Sac7d by
12
13 246 using CDR(s), a part of the CDR3 loop (10 residues) from a camel antibody specific
14
15 247 for lysozyme was inserted at places where there is a loop in Sac7d, and then the effect
16
17 248 of insertions on the chimeric proteins obtained was studied. This approach has
18
19 249 previously been deployed for other potential artificial binding proteins, such as
20
21 250 neocarzinostatin (NCS), single chain antibody (scFv), green fluorescent protein (GFP)
22
23 251 and ubiquitin (Inoue *et al.*, 2011, Kiss *et al.*, 2006, Nicaise *et al.*, 2004, Saerens *et al.*,
24
25 252 2005).
26
27
28
29

30 253

31
32 254 **Construction of the Sac7d protein mutants**

33
34 255 Previous studies with CDR inserting/grafting have been performed using
35
36 256 sequences of CDR3 of different lengths, truncated or not, originating from various
37
38 257 camel anti-lysozyme antibodies. The CDR3 of cAb-Lys3 camel antibody specific for
39
40 258 HEWL has been reported as ⁹⁹DSTIYASYEYECGHGLSTGGYGYDS¹²² (Desmyter,
41
42 259 *et al.*, 1996) with only the N-terminal part of this loop interacting with HEWL
43
44 260 (Transue *et al.*, 1998) providing about 70% of contacts. In order to transfer only the
45
46 261 region involved in HEWL recognition, the structure of cAb-Lys3 in complex with
47
48 262 HEWL (PDB code: 1MEL) was analyzed with the “Protein interfaces, surfaces and
49
50 263 assemblies” service (PISA) at the European Bioinformatics Institute
51
52 264 (http://www.ebi.ac.uk/pdbe/prot_int/pistart.html) (Krissinel and Henrick, 2007),
53
54 265 which determines interfacing residues in a complex. The peptide ¹⁰⁰STIYASYE¹⁰⁸
55
56
57
58
59
60

1
2
3 266 of the CDR3 region was identified as interacting with HEWL. A visual inspection of
4
5 267 the structure of the complex confirmed this analysis, but also that Cys109 is found in
6
7 268 the protruding part of this CDR3. To avoid an impaired cysteine, it was replaced with
8
9 269 a serine. Thus the peptide ¹⁰⁰STIYASYYES¹⁰⁹ was inserted onto three different loops
10
11 270 of Sac7d orientated towards DNA binding site; between the β 1 β 2 (mL1), β 3 β 4 (mL2),
12
13 271 and β 4 β 5 (mL3) strands (Figure 1).
14

15
16 272 The WT Sac7d and chimeras were cloned into the expression plasmid pFP1001
17
18 273 (Mouratou *et al.*, 2012) and produced with His-tags. The proteins accumulated in the
19
20 274 cytoplasm of *E. coli* strain DH5 α at 30°C after overnight growth and could be
21
22 275 purified to homogeneity in two steps by immobilized metal ion affinity
23
24 276 chromatography and gel filtration as described previously (Mouratou, *et al.*, 2007).
25
26 277 Since Sac7d has a DNA-binding activity, all the proteins were purified with buffers
27
28 278 containing 500 mM NaCl in order to prevent co-purification of DNA. The production
29
30 279 yields for WT Sac7d, mL2 and mL3 were 10, 15 and 9 mg per liter of shake-flask
31
32 280 culture, respectively, while for mL1 the expression yield was drastically affected
33
34 281 (0.25 mg/L).
35
36
37
38
39

40 41 283 **Characterization of proteins**

42
43 284 The proteins ran on a 15% acrylamide SDS/PAGE gel at the positions expected for
44
45 285 their calculated molecular masses, and their elution volumes from the gel filtration
46
47 286 column were consistent with monomeric species (data not shown).
48

49 50 51 288 *Secondary structure contents of proteins*

52
53
54 289 To evaluate whether anti-HEWL CDR3 insertions affected the structural integrity
55
56 290 of Sac7d, far-UV CD spectra were recorded from 190 to 260 nm. All the spectra were
57
58
59
60

1
2
3 291 characteristic of mostly beta-sheet proteins (Figure 2A). CD spectra of chimera were
4
5 292 all similar to the spectrum of WT Sac7d from this work and from a previous study
6
7 293 (Edmondson and Shriver, 2001).

8
9 294 Secondary structure predictions from CD spectra were made using the Dichroweb
10
11 295 software (Table 1). All proteins were predicted to contain percentages of β -sheet and
12
13 296 α -helix comparable to those deduced from previously resolved crystallographic
14
15 297 structures of WT Sac7d (PDB codes: 1AZP, 1CA5, 1WVL, 1WD1).

16
17 298 Overall, the CD analysis suggested that the structures of the three chimeras
18
19 299 remained unchanged compared to the structure of WT Sac7d.
20
21
22

23 300

24
25 301 *Thermal and pH stabilities of chimera compared to WT Sac7d*

26
27 302 Temperature-induced unfolding of proteins was carried out by monitoring the
28
29 303 ellipticity at 205 nm while gradually increasing the temperature (Figure 2B). Thermal
30
31 304 stabilities of mL1, mL2 and mL3 chimeras determined by analysis of transition curves
32
33 305 were of 66.3°C, 65.1°C and 60.9°C, respectively (Table 1). A T_m value of 90.4°C for
34
35 306 WT Sac7d was previously reported (Edmondson and Shriver, 2001). These results
36
37 307 indicate that CDR insertions in loops can be detrimental for Sac7d thermal stability.
38
39

40 308 Sac7d is an acidophilic (McCrary, *et al.*, 1996) and alkaliphilic protein (Behar, *et*
41
42 309 *al.*, 2013). To investigate whether CDR3 insertion had an effect on Sac7d pH stability,
43
44 310 CD spectra were recorded from 200 to 250 nm. It was observed that the CD spectra
45
46 311 for all the proteins remained largely unchanged at pH from 0 to at least 12, indicating
47
48 312 the presence of stable secondary structures (data not shown). CD spectra recorded at
49
50 313 pH 14 were entirely different for all the proteins and were characteristic of disordered
51
52 314 peptides. Figure 2C shows the residual unfolded fraction taking into account that the
53
54 315 unfolded state is reached at pH 14 for all the proteins. Surprisingly, this study
55
56
57
58
59
60

1
2
3 316 indicates that, contrary to thermal stability, the pH stability of Sac7d was unaffected
4
5 317 by CDR insertion at the three positions tested, further supporting the idea that
6
7 318 chimeras were correctly folded.
8

9
10 319

11 320 **Interaction of proteins with DNA**

12
13
14 321 Sac7d is a non-specific DNA binder and thus we wanted to check the functional
15
16 322 integrity of chimeras by measuring their ability to bind DNA. In addition, as chimeras
17
18 323 were shown well structured and stable, this analysis could be indicative of
19
20 324 conformations adopted by CDRs that could interfere with DNA binding surface due to
21
22 325 steric hindrances.
23
24

25 326

26 27 327 *Detection of DNA-binding activity by fluorescence*

28
29 328 DNA-Sac7d interaction occurs by contact between the minor groove of DNA and
30
31 329 the β -sheet surface composed of $\beta 3\beta 4\beta 5$ strands. A hydrophobic motif positioned on
32
33 330 this surface, which includes W24, is buried upon DNA-binding and its intrinsic
34
35 331 fluorescence is quenched (McAfee, *et al.*, 1996, Su *et al.*, 2000). To determine their
36
37 332 DNA-binding ability, all the proteins were incubated in the absence or presence of
38
39 333 calf thymus DNA and the emission fluorescence spectra were recorded from 300 to
40
41 334 400 nm (Figure 3A). The tryptophan fluorescence intensity was significantly
42
43 335 quenched for Sac7d in presence of DNA and a similar result was observed for mL3,
44
45 336 whereas for mL1 and mL2 the quenchings were less important. Moreover, in
46
47 337 agreement with structural analysis by CD, all the proteins showed the same maximal
48
49 338 emission wavelength, suggesting marginal structural modifications, and
50
51 339 concomitantly were slightly blue-shifted due to the burial of tryptophan upon DNA-
52
53 340 binding.
54
55
56
57
58
59
60

1
2
3 341 To determine the DNA-binding affinity, a constant concentration of proteins was
4
5 342 incubated with an increasing concentration of calf thymus DNA and the magnitude of
6
7 343 fluorescence quenching was recorded (Figure 3B). A nonlinear regression analysis to
8
9 344 fit the data was performed in order to calculate the affinity. A dissociation constant of
10
11 345 4.89×10^{-5} M was obtained for Sac7d (Table 1). This value is comparable to the
12
13 346 affinity of 5.37×10^{-5} M previously reported for Sac7d and calf thymus DNA
14
15 347 (McAfee, *et al.*, 1996). The mL3 protein showed a slightly lower dissociation constant
16
17 348 of 6.25×10^{-5} M. It was not possible to determine the binding parameters for mL1 and
18
19 349 mL2 proteins given that saturation was not reached, suggesting low affinities for
20
21 350 DNA.
22
23
24
25

26 27 352 *Detection of DNA-binding activity by electrophoretic mobility shift assay (EMSA)*

28
29 353 DNA-binding ability was also studied by EMSA (Figure 3C). Increasing quantities
30
31 354 of the proteins were incubated with 200 ng of DNA probe followed by
32
33 355 electrophoresis. Figure 3C shows that the DNA probe was visibly shifted even for the
34
35 356 lowest concentration of WT Sac7d tested ($0.6 \mu\text{M}$). No significant effect was
36
37 357 observed for the same concentration with mL3, but the more the protein concentration
38
39 358 increased the more it was retarded on the gel. No significant interaction for mL1 and
40
41 359 mL2 was observed at the higher concentration assayed.
42
43
44

45 360 46 47 361 **Interaction of chimeras with HEWL**

48
49 362 Finally, the interaction of chimeras with HEWL was investigated by ELISA and
50
51 363 SPR. Specific binding was obtained by ELISA between mL3 and HEWL, while no
52
53 364 signal was detected with WT Sac7d, mL1 or mL2 (Figure 4A). The affinity of mL3
54
55 365 for HEWL was determined by SPR (Table 1). Successive injections of increasing
56
57
58
59
60

1
2
3 366 concentrations of mL3 were carried out to obtain kinetic parameters. The sensorgram
4
5 367 showed a hyperbolic association curve characteristic of an interaction, while the
6
7 368 dissociation was fast (Figure 4B). The K_D value obtained was 6.7 μ M.
8

9
10 369

11 370 **DISCUSSION**

12
13
14 371 In this study, we have demonstrated that the extremophilic protein Sac7d
15
16 372 withstands insertion of ten residues at least for three of its short loops. This was
17
18 373 achieved by using an element of recognition from another protein, i.e. a CDR3 loop
19
20 374 fragment from an anti-HEWL camel antibody. Thereby, affinity transfer was possible
21
22 375 for one of the three positions tested.
23

24
25 376 The secondary structure content and pH stability were similar for chimeras and WT
26
27 377 Sac7d. Sac7d and its homologs show remarkable stabilities (temperature, pH,
28
29 378 chemicals) which initially guided our choice to use them to derive artificial affinity
30
31 379 proteins (Mouratou, *et al.*, 2007, Pecorari and Alzari, 2008). Several factors are
32
33 380 known to contribute to the stability of extremophilic proteins, such as hydrophobic
34
35 381 interactions, packing efficiency, salt-bridges, hydrogen bonds, reduction in the
36
37 382 entropy of folding (Vieille and Gregory Zeikus, 1996) and some of them have been
38
39 383 studied for Sac7d (Bedell *et al.*, 2005, Clark *et al.*, 2004, Clark *et al.*, 2007, Kahsai *et*
40
41 384 *al.*, 2005, McCrary *et al.*, 1998). Loop extensions are expected to destabilize proteins
42
43 385 because of the entropic cost associated with loop closure (Nagi and Regan, 1997,
44
45 386 Scalley-Kim *et al.*, 2003). A comparative analysis of 20 complete genomes reported
46
47 387 that thermophilic proteins tend to show deletions in exposed loop regions compared to
48
49 388 their mesophilic homologs (Thompson and Eisenberg, 1999). There are no mesophilic
50
51 389 homologs available for comparison with Sac7d (Razvi and Scholtz, 2006). In
52
53 390 addition, it has been reported for RNase H from *Thermus thermophilus* and
54
55
56
57
58
59
60

1
2
3 391 Rubredoxin from *Pyrococcus furiosus*, which are two other well-characterized
4
5 392 hyperthermostable proteins, that their short loops do not make an important
6
7 393 contribution to stability (Hernandez *et al.*, 2000, Hollien and Marqusee, 1999).
8
9 394 Nevertheless, superimposition of seven three-dimensional structures of Sac7d showed
10
11 395 that residues in loops have the largest root mean squared deviations (Bosch *et al.*,
12
13 396 2003). Furthermore, an amide hydrogen exchange study reported that the three loop
14
15 397 regions of Sac7d where we inserted the anti-HEWL CDR3 are the least stable and
16
17 398 most flexible regions (with the end of the C-terminal helix) of the protein (Kahsai, *et*
18
19 399 *al.*, 2005). We found that the midpoint temperature values of thermal unfolding for
20
21 400 the chimeras were about 30°C lower than that of WT Sac7d. The drops in thermal
22
23 401 stabilities for these mutants with extended loops are greater than for mutants of the
24
25 402 hydrophobic core previously reported (Clark, *et al.*, 2004), indicating that short loops
26
27 403 contribute to stability. This study demonstrated that CDR3 insertions were
28
29 404 significantly destabilizing for the three positions tested. Remarkably, mL3, the least
30
31 405 stable chimera ($T_m = 60.9$ °C) remained 9°C more stable than the mean T_m value
32
33 406 determined for a cured dataset of 65 mesostable proteins with known three-
34
35 407 dimensional structures (Folch *et al.*, 2010), and can thus still be regarded as a
36
37 408 thermostable protein.

38
39 409 Taken together, these results support the idea that the Sac7d scaffold is tolerant to
40
41 410 remodeling of its short loops, via introduction of a peptide stretch (here ten amino
42
43 411 acids), without considerable structural modifications, but with a destabilizing effect
44
45 412 that could be fatal for a protein less stable than Sac7d. As far as we know, this is the
46
47 413 first report of CDR3 insertion for an archaeal extremophilic scaffold protein, here
48
49 414 Sac7d.
50
51
52
53
54
55
56
57
58
59
60

1
2
3 415 Furthermore, the integrity of the DNA-binding function was demonstrated for mL3
4
5 416 by fluorescence measurements and EMSA, while for the other two chimeras it was
6
7 417 drastically reduced. In addition, thermal unfolding of chimeras occurred cooperatively
8
9 418 with a sharp transition for all chimeras, which is an indication of native-like structures
10
11 419 (Roy and Hecht, 2000). Our results support the idea that alteration of DNA binding
12
13 420 for mL1 and mL2 is more probably due to steric hindrances involving the CDR3
14
15 421 loops, which could be oriented toward the DNA-binding surface, than to an overall
16
17 422 structural change of Sac7d folding. Supporting this hypothesis, we also observed in
18
19 423 experimental three-dimensional structures of proteins with a similar topology to
20
21 424 Sac7d that their natural longer loops (~ 6-8 residues) equivalent to mL2 have
22
23 425 tendency to fold toward β -sheet 2 (Figure 5).
24
25

26
27 426 Another question we wanted to address in this work was: is the potential of each
28
29 427 loop to introduce recognition of a target equivalent? The cAb-Lys3 camel antibody
30
31 428 binds to HEWL with an affinity of 20 nM (Desmyter, *et al.*, 1996). We inserted the
32
33 429 stretch of 10 amino acids identified as interacting with HEWL from the CDR3 of this
34
35 430 antibody. According to our results, the three insertion positions tested in Sac7d
36
37 431 (⁹KG¹⁰, ²⁷GK²⁸ and ³⁷NG³⁸) were not equivalent. Chimera mL3 was able to bind
38
39 432 HEWL as indicated by ELISA and SPR experiments with an affinity of 6.7 μ M. This
40
41 433 result confirms the possibility of transferring CDR3s with specific binding properties
42
43 434 to alternative scaffolds such as Sac7d. Affinity values obtained here were similar to
44
45 435 those previously recorded (from 0.5 μ M to 7.6 μ M) for cAb-Lys3 CDR3 grafting or
46
47 436 insertion in NCS, scFv and GFP (Kiss, *et al.*, 2006, Nicaise, *et al.*, 2004, Saerens, *et*
48
49 437 *al.*, 2005). Weak affinities were expected considering that other regions of the cAb-
50
51 438 Lys3 antibody contributing to HEWL binding were not present in all the chimeras
52
53 439 studied. Another explanation could be that the inserted CDR3 region did not have the
54
55
56
57
58
59
60

1
2
3 440 possibility of forming a disulfide bridge between the scaffold frameworks and the Cys
4
5 441 of the CDR3 sequence (Inoue, *et al.*, 2011, Nicaise, *et al.*, 2004), constraining the
6
7 442 CDR3 conformation. We hypothesize that the orientation of CDR3 was determinant
8
9 443 to transfer HEWL binding into the mL3 protein. As we assume that loops 1 and 2
10
11 444 were bent causing steric hindrance for DNA binding, they probably did not have the
12
13 445 optimal conformation to penetrate the active site of HEWL. The opposite effect was
14
15 446 observed for loop 3, which seemed accessible for HEWL binding and did not interfere
16
17 447 with DNA binding. Determining the structure of the chimeras might lead to a better
18
19 448 understanding of the differences observed.
20
21

22
23 449 In summary, we report the successful transfer of binding properties by CDR
24
25 450 insertion in an extremophilic scaffold protein. With this approach, together with our
26
27 451 recent report (Correa *et al.* 2014), we were able to design binding sites into Sac7d that
28
29 452 recognize concave epitopes. Considering the small size of Sac7d (7 kDa), its tolerance
30
31 453 to loop remodeling is remarkable. We anticipate that CDR(s) from antibodies in
32
33 454 combination with randomized surface(s) and/or loop(s) may be used as potential
34
35 455 recognition elements in Sac7d to help selections to converge toward binding of the
36
37 456 corresponding epitope on antigen of interest.
38
39
40
41

457

458 **ACKNOWLEDGMENTS**

459 We thank Dr. Yves-Henri Sanejouand and Johann Hendrickx (University of
46
47 460 Nantes, FRE3478 CNRS) for helpful discussions.
48
49

461

462 **FUNDING INFORMATION**

463 This work was supported by the Pasteur Institute (Paris, France), with a
464
465 postdoctoral fellowship for SP, and by “La Région des Pays de la Loire”.

1
2
3
4 465

5 466 **CONFLICT-OF-INTEREST DISCLOSURE**

6
7 467 F.P. is co- inventor of a patent that has been filed by the Institut Pasteur and CNRS
8
9 468 describing generation of binders from Sac7d and its homologs. F.P. is a co-founder of
10
11 469 a spin-off company of the Institut Pasteur / CNRS / Université de Nantes that has a
12
13 470 license agreement.
14

15 471
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

472 **REFERENCES**

473

474 Batori V., Koide A. and Koide S. (2002) *Protein Eng*, **15**, 1015-1020.475 Bedell J.L., Edmondson S.P. and Shriver J.W. (2005) *Biochemistry*, **44**, 915-925.

476 Behar G., Bellinzoni M., Maillason M., Paillard-Laurance L., Alzari P.M., He X.,

477 Mouratou B. and Pecorari F. (2013) *Protein Eng Des Sel*, **26**, 267-275.

478 Bes C., Troadec S., Chentouf M., Breton H., Dominique Lajoix A., Heitz F., Gross R.,

479 Pluckthun A. and Charades T. (2006) *Biochem Biophys Res Commun*, **343**, 334-

480 344.

481 Beste G., Schmidt F.S., Stibora T. and Skerra A. (1999) *Proc Natl Acad Sci U S A*, **96**,

482 1898-1903.

483 Binz H.K., Amstutz P., Kohl A., Stumpp M.T., Briand C., Forrer P., Grutter M.G. and

484 Pluckthun A. (2004) *Nat Biotechnol*, **22**, 575-582.485 Binz H.K., Amstutz P. and Pluckthun A. (2005) *Nat Biotechnol*, **23**, 1257-1268.486 Bosch D., Campillo M. and Pardo L. (2003) *Journal of computational chemistry*, **24**,

487 682-691.

488 Buddelmeijer N., Krehenbrink M., Pecorari F. and Pugsley A.P. (2009) *J Bacteriol*,489 **191**, 161-168.490 Clark A.T., McCrary B.S., Edmondson S.P. and Shriver J.W. (2004) *Biochemistry*,491 **43**, 2840-2853.492 Clark A.T., Smith K., Muhandiram R., Edmondson S.P. and Shriver J.W. (2007) *J*493 *Mol Biol*, **372**, 992-1008.

494 Correa A., Pacheco S., Mechaly Ariel E., Obal G., Béhar G., Mouratou B., Opezzo

495 P., Alzari P.M. and Pecorari F. (2014) *PLoS One*, **9**, e97438.

- 1
2
3 496 Desmyter A., Transue T.R., Ghahroudi M.A., Thi M.H., Poortmans F., Hamers R.,
4
5 497 Muyltermans S. and Wyns L. (1996) *Nat Struct Biol*, **3**, 803-811.
6
7 498 Edmondson S.P. and Shriver J.W. (2001) *Methods Enzymol*, **334**, 129-145.
8
9 499 Folch B., Dehouck Y. and Rooman M. (2010) *Biophys J*, **98**, 667-677.
10
11 500 Gebauer M. and Skerra A. (2009) *Curr Opin Chem Biol*, **13**, 245-255.
12
13 501 Greenfield N.J. (2006) *Nature protocols*, **1**, 2527-2535.
14
15 502 Hernandez G., Jenney F.E., Adams M.W. and LeMaster D.M. (2000) *Proc Natl Acad*
16
17 *Sci USA*, **97**, 3166-3170.
18
19 503
20 504 Hollien J. and Marqusee S. (1999) *Biochemistry*, **38**, 3831-3836.
21
22 505 Holm L. and Rosenström P. (2010) *Nucleic Acids Res*, **38**, W545-W549.
23
24 506 Inoue H., Ihara A., Takahashi H., Shimada I., Ishida I. and Maeda Y. (2011) *Protein*
25
26 *Sci*, **20**, 1971-1981.
27
28 507
29 508 Kahsai M.A., Martin E., Edmondson S.P. and Shriver J.W. (2005) *Biochemistry*, **44**,
30
31 13500-13509.
32
33 510 Karlsson R. and Falt A. (1997) *J Immunol Methods*, **200**, 121-133.
34
35 511 Kiss C., Fisher H., Pesavento E., Dai M., Valero R., Ovecká M., Nolan R., Phipps
36
37 M.L., Velappan N. and Chasteen L. (2006) *Nucleic Acids Res*, **34**, e132-e132.
38
39 512
40 513 Koide A., Bailey C.W., Huang X. and Koide S. (1998) *J Mol Biol*, **284**, 1141-1151.
41
42 514 Koide A., Wojcik J., Gilbreth R.N., Hoey R.J. and Koide S. (2012) *J Mol Biol*, **415**,
43
44 393-405.
45
46 515
47 516 Krehenbrink M., Chami M., Guilvout I., Alzari P.M., Pecorari F. and Pugsley A.P.
48
49 (2008) *J Mol Biol*, **383**, 1058-1068.
50
51 517
52 518 Krissinel E. and Henrick K. (2007) *J Mol Biol*, **372**, 774-797.
53
54 519 Kumar S. and Nussinov R. (2001) *Cellular and Molecular Life Sciences CMLS*, **58**,
55
56 1216-1233.
57
58
59
60

- 1
2
3 521 Ladurner A.G. and Fersht A.R. (1997) *J Mol Biol*, **273**, 330-337.
4
5 522 McAfee J.G., Edmondson S.P., Zegar I. and Shriver J.W. (1996) *Biochemistry*, **35**,
6
7 523 4034-4045.
8
9 524 McCrary B.S., Bedell J., Edmondson S.P. and Shriver J.W. (1998) *J Mol Biol*, **276**,
10
11 525 203-224.
12
13 526 McCrary B.S., Edmondson S.P. and Shriver J.W. (1996) *J Mol Biol*, **264**, 784-805.
14
15 527 Mouratou B., Behar G., Paillard-Laurance L., Colinet S. and Pecorari F. (2012)
16
17 528 *Methods Mol Biol*, **805**, 315-331.
18
19 529 Mouratou B., Schaeffer F., Guilvout I., Tello-Manigne D., Pugsley A.P., Alzari P.M.
20
21 530 and Pecorari F. (2007) *Proc Natl Acad Sci U S A*, **104**, 17983-17988.
22
23 531 Nagi A.D. and Regan L. (1997) *Fold Des*, **2**, 67-75.
24
25 532 Nicaise M., Valerio-Lepiniec M., Minard P. and Desmadril M. (2004) *Protein Sci*, **13**,
26
27 533 1882-1891.
28
29 534 Nord K., Gunneriusson E., Ringdahl J., Stahl S., Uhlen M. and Nygren P.A. (1997)
30
31 535 *Nat Biotechnol*, **15**, 772-777.
32
33 536 Pecorari F. and Alzari P.M. (2008) *Patent Publication Nos PCT/IB2007/004388*.
34
35 537 Razvi A. and Scholtz J.M. (2006) *Protein Sci*, **15**, 1569-1578.
36
37 538 Roy S. and Hecht M.H. (2000) *Biochemistry*, **39**, 4603-4607.
38
39 539 Saerens D., Pellis M., Loris R., Pardon E., Dumoulin M., Matagne A., Wyns L.,
40
41 540 Muyltermans S. and Conrath K. (2005) *J Mol Biol*, **352**, 597-607.
42
43 541 Scalley-Kim M., Minard P. and Baker D. (2003) *Protein Sci*, **12**, 197-206.
44
45 542 Schilling J., Schöppe J. and Plückthun A. (2014) *J Mol Biol*, **426**, 691-721.
46
47 543 Su S., Gao Y.G., Robinson H., Liaw Y.C., Edmondson S.P., Shriver J.W. and Wang
48
49 544 A.H. (2000) *J Mol Biol*, **303**, 395-403.
50
51 545 Thompson M.J. and Eisenberg D. (1999) *J Mol Biol*, **290**, 595-604.
52
53
54
55
56
57
58
59
60

1
2
3 546 Transue T.R., De Genst E., Ghahroudi M.A., Wyns L. and Muyldermans S. (1998)

4
5 547 *Proteins*, **32**, 515-522.

6
7 548 Vieille C. and Gregory Zeikus J. (1996) *Trends Biotechnol*, **14**, 183-190.

8
9 549 Whitmore L. and Wallace B. (2004) *Nucleic Acids Res*, **32**, W668-W673.

10
11 550 Whitmore L. and Wallace B.A. (2008) *Biopolymers*, **89**, 392-400.

12
13
14 551

15
16 552

17
18 553

19
20
21 554

22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

555 **LEGENDS TO FIGURES**

556 **Figure 1.** Structure and sequence of Sac7d. The structure of Sac7d, which folds as a
557 SH3-like five-stranded incomplete β -barrel capped by a C-terminal α -helix, is
558 represented in cartoons. Arrows indicate the position where the anti-HEWL CDR3 of
559 the cAb-Lys3 camel antibody was inserted. The β -sheet composed of β 3 β 4 β 5-strands
560 is the DNA-binding surface.

562 **Figure 2.** Analysis of secondary structure and stability of chimeric proteins. Far-UV
563 spectra (A), temperature- (B) and pH-induced unfolding (C) of Sac7d and chimeric
564 proteins analyzed by circular dichroism. Line codes in the graphs correspond to Sac7d
565 (—), mL1 (—), mL2 (···) and mL3 (---).

567 **Figure 3.** Analysis of the interaction between DNA and chimeric proteins. (A)
568 Intrinsic tryptophan fluorescence in absence (black line) or presence (gray line) of calf
569 thymus DNA. (B) Determination of DNA-binding affinity of Sac7d and chimera. The
570 fluorescence quenching was measured at 345 nm. Quenching values are plotted versus
571 increasing concentration of calf thymus DNA. Line codes in the graphs correspond to
572 Sac7d (—), mL1 (—), mL2 (···) and mL3 (---). (C) Electrophoretic mobility shift
573 assays (EMSA). The DNA probe obtained by PCR was incubated with increasing
574 concentrations of proteins and subjected to electrophoresis in polyacrylamide gel.

576 **Figure 4.** Analysis of HEWL binding. (A) ELISA binding assay of Sac7d and
577 chimeric proteins (5 μ M) against HEWL (black bars) or casein (white bars)
578 immobilized on the plate. The error bars correspond to the interval of confidence of
579 the mean of three measurements. (B) SPR analysis of mL3 binding to HEWL.

1
2
3 580 Different concentrations of mL3 (0.28, 0.56, 1.13, 2.25, 4.5, 8.97, 17.95, 35.9 μ M),
4
5 581 followed by washing with buffer flow are shown. The global fit is indicated by dashed
6
7 582 lines.
8

9 583

10
11 584 **Figure 5.** Superimpositions of experimental structures of proteins structurally
12
13 585 homologous to Sac7d having a loop equivalent to mL2 with 6-8 residues. (A) Sac7d is
14
15 586 colored in green (pdb code 1wd1), homologs in yellow (pdb codes 1dz1, 1e0b, 3kup,
16
17 587 and 3q6s), loops of homologs equivalent to mL2 loop in red and DNA bound by WT
18
19 588 Sac7d in grey. (B) Zoom-in of (A) to show how are folded loops of homologs. (C)
20
21 589 Another orientation of superimpositions, without structures of homologs for clarity.
22
23 590 Homologous proteins were identified using Sac7d structure (pdb code 1wd1) and Dali
24
25 591 server (Holm and Rosenström, 2010). All structural representations were prepared
26
27 592 with PyMOL (www.pymol.org).
28
29
30
31

32 593

33
34 594
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

TABLES

595

596

Table 1. Secondary structure content, parameter of thermal stability and affinity of Sac7d and chimeric proteins.

Protein	α -Helix (%)	β -Sheet (%)	Turns (%)	Unordered (%)	T_m^a (°C)	DNA binding ^a (x 10 ⁻⁵ M)	HEWL binding ^b (x 10 ⁻⁶ M)
Sac7d	6	30	29	35	90.4 ^c	4.89 (± 0.6)	ND
mL1	6	32	32	30	66.3 (± 0.4)	ND	ND
mL2	7	35	26	32	65.1 (± 0.4)	ND	ND
mL3	10	30	28	32	60.9 (± 0.4)	6.25 (± 2.4)	6.7

^aValues calculated from experimental data. The points were fitted to nonlinear regression curves and the quality criteria were r^2 squared >0.98 and small values for the standard deviation indicated in parentheses. Data represent the result of two independent experiments.

^b K_D value recorded by SPR experiments.

^c From Edmondson and Shriver (2001)

N.D.: not detectable

597

S. Pacheco *et al.*

27




Figure 1. Structure and sequence of Sac7d. The structure of Sac7d, which folds as a SH3-like five-stranded incomplete β -barrel capped by a C-terminal α -helix, is represented in cartoons. Arrows indicate the position where the anti-HEWL CDR3 of the cAb-Lys3 camel antibody was inserted. The β -sheet composed of β 3 β 4 β 5-strands is the DNA-binding surface.

118x78mm (300 x 300 DPI)

review




Figure 2. Analysis of secondary structure and stability of chimeric proteins. Far-UV spectra (A), temperature- (B) and pH-induced unfolding (C) of Sac7d and chimeric proteins analyzed by circular dichroism. Line codes in the graphs correspond to Sac7d (—), mL1 (---), mL2 (···) and mL3 (—·—).
50x14mm (300 x 300 DPI)

Peer Review




Figure 3. Analysis of the interaction between DNA and chimeric proteins. (A) Intrinsic tryptophan fluorescence in absence (black line) or presence (gray line) of calf thymus DNA. (B) Determination of DNA-binding affinity of Sac7d and chimera. The fluorescence quenching was measured at 345 nm. Quenching values are plotted versus increasing concentration of calf thymus DNA. Line codes in the graphs correspond to Sac7d (—), mL1 (---), mL2 (···) and mL3 (—·—). (C) Electrophoretic mobility shift assays (EMSA). The DNA probe obtained by PCR was incubated with increasing concentrations of proteins and subjected to electrophoresis in polyacrylamide gel.

135x103mm (300 x 300 DPI)




Figure 4. Analysis of HEWL binding. (A) ELISA binding assay of Sac7d and chimeric proteins ($5 \mu\text{M}$) against HEWL (black bars) or casein (white bars) immobilized on the plate. The error bars correspond to the interval of confidence of the mean of three measurements. (B) SPR analysis of mL3 binding to HEWL. Different concentrations of mL3 ($0.28, 0.56, 1.13, 2.25, 4.5, 8.97, 17.95, 35.9 \mu\text{M}$), followed by washing with buffer flow are shown. The global fit is indicated by dashed lines.
58x19mm (300 x 300 DPI)




Figure 5. Superimpositions of experimental structures of proteins structurally homologous to Sac7d having a loop equivalent to mL2 with 6-8 residues. (A) Sac7d is colored in green (pdb code 1wd1), homologs in yellow (pdb codes 1dz1, 1e0b, 3kup, and 3q6s), loops of homologs equivalent to mL2 loop in red and DNA bound by WT Sac7d in grey. (B) Zoom-in of (A) to show how are folded loops of homologs. (C) Another orientation of superimpositions, without structures of homologs for clarity. Homologous proteins were identified using Sac7d structure (pdb code 1wd1) and Dali server (Holm and Rosenström, 2010). All structural representations were prepared with PyMOL (www.pymol.org).

60x19mm (300 x 300 DPI)